The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Its great news, for men that may suffer PC in the near future. Trial starts in spring 24 and recruiting in late 24. As you say, PYC not involved with the sceening process. PC has already a lot of drugs on the market or heading towards it. You could hypothesise that in the future other drugs will come to the market, and they will need evaluating, and in conjunction with Project Optimus. If PYC will be involved, who knows?
I read with interest what either side here are saying. There are some that are saying that these forums are to debate if a share is to be bought, sold or hold? I am guessing this statement is from the negative side of the spectrum? However as yet, i have not seen 1 poster from any persuasion give their 2 pence worth about buying, selling or holding.
Lots of questions answered.
The 30% shortfall and answer about subsidy for the Blackpool trial seems to hold water? I am sure others will have a different POV on this?
Possible new collab with sheffield Uni in the works?
Reading between the lines, the idea about looking at Neutrapina and G-CSF came from thier collab with Doseme?
They did not answer about conversation rates, though they did show a slide showing 19 projects then to 5 contracts? Unless i am reading that wrong, that is approx 25%? So if they have £1M potential booked revenues, they could expect £250k in contracts? Millen did say they were so far "in line" with market expectations .
Oh, and Peter does not pronounce his G's!
Laura, there was a news letter sent out last weekend, but it just mentioned the stuff that we already know about. Doseme is well over due, and i very much doubt they will reply regarding the VAL merger, as its nothing to do with PYC.
Acker, VAL has shot up recently, but PYC is really lagging, apart from the spike from 1p to 3p ( before the VAL rise ) PYC has fallen back and i do not see any "shadowing".
Its a wonder as to why they have decided to change from a Oxf address, to a address just outside Didcot?
They mentioned "flexible" working and great transport links to Oxf and London, however, when they were in Oxf, they also had good links, as already in Oxf and either train to London, or scoot down the M40?
Being near Didcot, yep, Padd is only 40 mins away, Oxf is 20 mins, but with the Oxf traffic being a complete nightmare as 2 long standing roadworks on the west of the city are being carried out at the same time.
Jim lives in High Wyc, and instead of going down the M40 to the old office, he'd have to now come at least part of the way, cross country to get to new base.
I know that Milton Park is actively trying to get more "science and tech" companies in to their portfolio as they get grants from HMGov for this. Not sure if the companies involved get these grants?
I do not know what they were paying for their space at the old base, but this is a possible breakdown in prices at Bee House.
Clear Membership - £70 + VAT pcm
20 hours a month in HoneyComb Co-Working space
Superfast connectivity
Includes:
Mail handling
Unlimited refreshments
Reasonable printer usage
Events schedule designed to assist small and growing businesses.
Lockers
Optional Additional Costs
Golden, Amber and Clear can buy additional days at £30 + VAT a day (8 hours)
Register your company at the Bee House for £10 + VAT pcm*
Telephone answering service available for £75 + VAT pcm (08:30-17:00) Administration fee £180. Refundable deposit of £220
Can only conclude that they have moved due to this workspace being cheaper?
Maybe because of CV19 when they probably worked from home, they paid for the old base, and it was not being used, hence the need for flexible working?
Its near impossible to copy the full text. The conclusion is as follows...... A PK-TGI model that describes all the PK and TGI data available for mANK-101 across numerous
different studies was developed. The final model was able to describe all the efficacy studies done with
different doses, schedules, injection sites and starting volumes well. The PK modelling highlighted the
lower systemic bioavailability of alum anchored mIL12/ABP versus free mIL12/ABP and also highlighted
that for alum anchored mIL12/ABP the absorption rate into plasma is significantly slower than its
elimination from plasma. Furthermore, the biomarker analysis conducted is consistent with a mechanism
of drug action of tumour cell death mediated by IL-12 mediated T-cell activation.
If people go to Ankyra website and look for the science tab. Move down the page, beyond the youtube video and find Posters and Presentations, the link is directly under that.